Sun Pharmaceutical Industries has launched Fexuprazan tablets 40 mg in India under the brand name ‘FEXUCLUE’. FEXUCLUE, a novel potassium competitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.
The company has obtained rights from Daewoong Pharmaceutical Co, Korea to manufacture and commercialise FEXUCLUE (Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.
Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.
